Financial Advisory Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Financial Advisory Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-625	Closed	-$11K	–	65
2016 Q3	$11K	Hold	625	–	–	﹤0.01%	63
2016 Q2	$7K	Buy	625 +125	+25%	+$2.46K	﹤0.01%	59
2016 Q1	$356K	Hold	500	–	–	0.17%	44
2015 Q4	$13K	Hold	500	–	–	0.01%	59
2015 Q3	$23K	Sell	500 -125	-20%	-$4.71K	0.01%	51
2015 Q2	$20K	Hold	625	–	–	0.01%	50
2015 Q1	$20K	Hold	625	–	–	0.01%	49
2014 Q4	$24K	Buy	625 +125	+25%	+$3.44K	0.01%	48
2014 Q3	$13K	Hold	500	–	–	0.01%	53
2014 Q2	$15K	Buy	+500	New	+$16.2K	0.01%	54
2013 Q4	–	Sell	-500	Closed	-$27K	–	54
2013 Q3	$27K	Buy	+500	New	+$29.1K	0.02%	46

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Financial Advisory Group's NAVB Position: Q4 2016 in Review

Financial Advisory Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2016, closing a stake of 625 shares — an estimated $11K sold.

Financial Advisory Group first reported a position in NAVB in Q3 2013 and held it in 11 quarters. The position peaked at $356K in Q1 2016. 55 funds tracked by Wall St. Rank hold NAVB as of Q4 2016.

Financial Advisory Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
Financial Advisory Group sold 625 Navidea Biopharmaceuticals Inc. shares in Q4 2016, an estimated $11K.
Financial Advisory Group first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 11 quarters.
Financial Advisory Group's Navidea Biopharmaceuticals Inc. position peaked at $356K in Q1 2016.
55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2016.

Based on Financial Advisory Group's 13F filing for Q4 2016, filed 5 Jan 2017.